Polyrizon Reports Positive Pre-Clinical Results For PL-14, Showing Strong Allergen-Blocking Efficacy

Polyrizon Ltd., a biotechnology company developing intranasal products using its proprietary Capture & Contain (C&C) platform, has reported encouraging results from a recent preclinical study evaluating its PL-14 Allergy Blocker formulation. The study was designed to simulate allergen exposure and assess the ability of PL-14 to prevent allergens from penetrating through a hydrogel barrier. In the experiment, Der p 1, a major house dust mite allergen, was applied to the surface of the PL-14 formulation, and samples were collected beneath the hydrogel at multiple time points to measure allergen penetration. 

The results demonstrated that PL-14 effectively limited allergen diffusion over time, forming a strong nasal barrier against Der p 1. After one hour, only 1.07% of the allergen passed through, while after two hours, penetration remained minimal at 1.14%, and even after four hours, diffusion was limited to just 13.6%. These findings underscore the potential of PL-14 to provide effective protection during the critical early hours of allergen exposure, when immune reactions are most likely to occur. Notably, the allergen load used in the study was estimated to be tens of times higher than typical real-world exposure levels during allergy seasons, suggesting that PL-14 may offer robust protection even under extreme conditions.

The allergy immunotherapy market is projected to grow significantly in the coming years. According to a report by Future Market Insights, the market is expected to increase from USD 1.9 billion in 2025 to USD 4.2 billion by 2035, expanding at a compound annual growth rate of 7.9%. This growth is largely driven by the rising prevalence of allergies worldwide, advancements in treatment methodologies, and increasing awareness of immunotherapy as an effective long-term solution. 

Tomer Izraeli, CEO of Polyrizon, noted that the company’s innovative C&C platform is designed to form a protective hydrogel layer that captures and contains airborne allergens before they reach the nasal mucosa. He emphasized that these preclinical results reinforce the potential of PL-14 as a frontline preventive solution for allergic rhinitis and other nasal allergies. Polyrizon continues to advance its preclinical development program and plans to initiate clinical studies to support regulatory and clinical pathways for PL-14 and other candidates within its C&C platform.